Skip to main content
. 2016 May 6;23(5):506–510. doi: 10.1097/GME.0000000000000592

TABLE 1.

Participant demographics and baseline characteristics

Parameter Vaginal E2 softgel (N = 24) Placebo (N = 24)
Age, y 62.4 ± 5.7 62.6 ± 7.3
BMI, kg/m2 26.4 ± 3.9 27.4 ± 3.4
Estradiol, pg/mLa 8.38 ± 9.54 6.96 ± 7.56
Parabasal cells, % 62.5 ± 40.1 64.6 ± 38.8
Superficial cells, % 1.7 ± 2.4 0.2 ± 1.0
Intermediate cells, % 35.8 ± 38.3 35.2 ± 38.4
pH 6.00 6.13
MBS (mean severity scoreb) 2.52 2.58
VVA symptoms (mean severity scoreb)
 Vaginal dryness 2.292 2.375
 Vaginal and/or vulvar irritation/itching 0.875 1.333
 Pain, burning, or stinging when urinating 0.583 0.625
Sexually active womenc
 Vaginal pain with sexual activity (mean severity score) 2.083 2.333
 Vaginal bleeding with sexual activity, % 25 33.33

Data are presented as the mean ± SD, except where noted.

BMI, body mass index.

aValues below 10 pg/mL were set to 0.0.

bSubjectively assessed as 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

cn = 12 women for each study arm sexually active at baseline.